MX2021016052A - Formulación transdérmica para el tratamiento del dolor y/o la inflamación. - Google Patents

Formulación transdérmica para el tratamiento del dolor y/o la inflamación.

Info

Publication number
MX2021016052A
MX2021016052A MX2021016052A MX2021016052A MX2021016052A MX 2021016052 A MX2021016052 A MX 2021016052A MX 2021016052 A MX2021016052 A MX 2021016052A MX 2021016052 A MX2021016052 A MX 2021016052A MX 2021016052 A MX2021016052 A MX 2021016052A
Authority
MX
Mexico
Prior art keywords
inflammation
pain
treatment
transdermal formulation
transdermal
Prior art date
Application number
MX2021016052A
Other languages
English (en)
Inventor
Joseph M Fracassi
Thomas J Scarlata
Original Assignee
Nexzol Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexzol Pharma Inc filed Critical Nexzol Pharma Inc
Publication of MX2021016052A publication Critical patent/MX2021016052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen formulaciones transdérmicas de fitocannabinoides y métodos para usarlos en el tratamiento del dolor y/o la inflamación.
MX2021016052A 2019-06-28 2019-06-28 Formulación transdérmica para el tratamiento del dolor y/o la inflamación. MX2021016052A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/040011 WO2020263285A1 (en) 2019-06-28 2019-06-28 Transdermal formulation for the treatment of pain and/or inflammation

Publications (1)

Publication Number Publication Date
MX2021016052A true MX2021016052A (es) 2022-04-18

Family

ID=74059780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016052A MX2021016052A (es) 2019-06-28 2019-06-28 Formulación transdérmica para el tratamiento del dolor y/o la inflamación.

Country Status (4)

Country Link
AU (1) AU2019454044A1 (es)
CA (1) CA3144239A1 (es)
MX (1) MX2021016052A (es)
WO (1) WO2020263285A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2760128A1 (en) * 2009-04-29 2010-11-04 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
JP2018505912A (ja) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
EP3442515A4 (en) * 2016-04-12 2019-12-04 Little Green Pharma Ltd Liposomal preparation and treatment methods

Also Published As

Publication number Publication date
WO2020263285A1 (en) 2020-12-30
CA3144239A1 (en) 2020-12-30
AU2019454044A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
EP3684353A4 (en) TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
AU2018322319A1 (en) Antisense oligomers for treatment of conditions and diseases
PH12018502634A1 (en) Topical compositions of apremilast
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
CA3010887A1 (en) Axl-specific antibody-drug conjugates for cancer treatment
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
EP3860621A4 (en) IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY
MX2021010989A (es) Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica.
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021016050A (es) Formulaciones transdermicas.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2022000712A (es) Moduladores de nlrp3.
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
WO2018187698A3 (en) Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
EP4138852A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
PH12018000077B1 (en) A pharmaceutical composition for neuropathic pain
MX2021008941A (es) Moduladores gpr35.
MX2021007063A (es) Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral.